



This list of clinical research protocols relating to sarcomas is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at <http://cancermet.nci.nih.gov/trialsrbc.sbtml>.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

CLINICAL RESEARCH PROTOCOLS FOR SARCOMAS

Phase III Trials

SWOG-S0033 Phase III Randomized Study of Two Different Doses of STI571 in Patients With CD117 Expressing Metastatic or Unresectable Gastrointestinal Stromal Tumor

Chairperson: George Daniel Demetri. Telephone: 617-632-2200. Lead organization: Cancer and Leukemia Group B. Age range: 15 and over.

NCI-00-C-0092 Phase III Pilot Randomized Study of Filgrastim-SD/01 Versus Filgrastim (G-CSF) With Concurrent Chemotherapy in Patients With Newly Diagnosed Sarcoma

Chairperson: Ramzi Dagher. Telephone: 301-594-4791. Lead organization: Division of Clinical Sciences. Age range: 25 and under at diagnosis.

Phase II Trials

CHNMC-IRB-94072, NCI-V94-0545 Phase II Pilot Study of High-Dose Doxorubicin and Ifosfamide Followed by High-Dose Melphalan and Cisplatin, Each With Autologous Peripheral Blood Stem Cell Support, in Patients With High-Risk and Recurrent Sarcomas

Chairperson: George Somlo. Telephone: 626-359-8111. Lead organization: Beckman Research Institute, City of Hope. Age range: 10 to 55.

NCI-99-C-0145, NCI-T99-0067 Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor

Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity

Chairperson: H. Richard Alexander, Jr. Telephone: 301-496-2195. Lead organization: Division of Clinical Sciences. Age range: 15 and over.

BRI-MF-2 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Fibrous Histiocytoma

Chairperson: Stanislaw R. Burzynski. Telephone: 713-335-5697. Lead organization: Burzynski Research Institute. Age range: 6 months and over.

BRI-SA-2 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Soft Tissue Sarcoma

Chairperson: Stanislaw R. Burzynski. Telephone: 713-335-5697. Lead organization: Burzynski Research Institute. Age range: 6 months and over.

MSKCC-99077, NCI-H00-0052 Phase II Study of Autologous Tumor Cell Derived Heat Shock Protein Peptide Vaccine in Patients With Recurrent Soft Tissue Sarcoma

Chairperson: Robert Maki. Telephone: 212-639-7900. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: over 18.

CAN-OTT-9401, NCI-V94-0566 Phase II Study of Cisplatin, Doxorubicin, and Tamoxifen (CAT) in Patients With Incurable Soft Tissue Sarcoma, Glioma, Mesothelioma, Hepatoma, Thyroid Cancer, or Adrenal Cancer

Chairperson: Stan Z. Gertler. Telephone: 613-737-7700. Lead

organization: Ottawa Regional Cancer Centre - Civic Campus. Age range: 65 and under.

SWS-SAKK-57/93, EU-93004

Phase II Study of High-Dose Ifosfamide and Doxorubicin in Patients With Advanced Soft Tissue or Gynecological Sarcoma

Chairperson: Serge Leyvraz. Telephone: 21-314-01-50. Lead organization: Swiss Institute for Applied Cancer Research. Age range: 18 to 70.

CAN-NCIC-IND136, NCI-NCIC-136 Phase II Study of Flavopiridol in Patients With Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma

Chairperson: Donald G. Morris. Telephone: 403-670-1707. Lead organization: NCIC-Clinical Trials Group. Age range: 18 and over.

MSKCC-99027, NCI-G99-1576

Phase II Study of Gemcitabine, Docetaxel, and Filgrastim (G-CSF) in Patients With Recurrent or Persistent Unresectable Uterine Leiomyosarcoma or Unresectable Leiomyosarcoma of Other Primary Sites

Chairperson: Martee L. Hensley. Telephone: 212-639-6555. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

CPMC-IRB-8100, NCI-V98-1511 Phase II Study of Irinotecan in Patients With Stage IV or Recurrent Soft Tissue Sarcoma

Chairperson: Robert N. Taub. Telephone: 212-305-4076. Lead organization: Herbert Irving Comprehensive Cancer Center. Age range: 18 and over.

MSKCC-99047, NCI-G99-1664

Phase II Study of Isolated Limb Infusion With Melphalan and Dactinomycin in Patients With Primary or Recurrent, Unresectable Regional Melanoma or Soft Tissue Sarcoma of the Extremity

Chairperson: Mary Susan Brady. Telephone: 212-639-8347. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: over 18.

SCCC-89032, NCI-V92-0066

Phase II Study of Neoadjuvant Chemotherapy With Intra-Arterial CDDP and Intravenous DOX in Patients With Resectable Soft Tissue Sarcoma of the Extremity

Chairperson: Pasquale W. Benedetto. Telephone: 305-243-4945. Lead organization: Sylvester Cancer Center, University of Miami. Age range: 18 and over.

SUPERGEN-RFS2000-24, MDA-DM-99109 Phase II Study of Nitrocamptothecin in Patients With Locally Advanced or Metastatic Gastrointestinal Leiomyosarcomas or Other Soft Tissue Sarcomas

Chairperson: Show-Li Sun. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: not specified.

UCCRC-10227, UCCRC-T99-0088, NCI-T99-0088 Phase II Study of O6-Benzylguanine and Carmustine in Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Chairperson: Christopher W. Ryan. Telephone: 773-834-1676. Lead organization: University of Chicago Cancer Research Center. Age range: 18 and over.

DFCI-99083, NCI-G99-1629

Phase II Study of Rosiglitazone in Patients With Liposarcoma

Chairperson: George Daniel Demetri. Telephone: 617-632-3985. Lead organization: Dana-Farber Cancer Institute. Age range: 18 and over.

DFCI-00002, NCI-330 Phase II Study of SU5416 in Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Chairperson: George Daniel Demetri. Telephone: 617-632-3985. Lead organization: Dana-Farber Cancer Institute. Age range: 18 and over.

CPMC-IRB-8358, NCI-V98-1510 Phase II Study of Temozolomide in Previously Treated Patients With Unresectable, Stage IV or Recurrent Soft Tissue Sarcoma

Chairperson: Robert N. Taub. Telephone: 212-305-4076. Lead organization: Herbert Irving Comprehensive Cancer Center. Age range: 18 and over.

CCC-CO-9672, NCI-G97-1217 Phase II Study of Whole Body Hyperthermia and Ifosfamide(IFF)/Carboplatin(CBDCA)/Etoposide (P-16) in Patients With Advanced Malignant Sarcoma

Chairperson: H. Ian Robins. Telephone: 608-263-1416. Lead organization: University of Wisconsin Comprehensive Cancer Center. Age range: 18 to 65.

Phase I Trials

MDA-ID-95225, NCI-G99-1606 Phase I Pilot Study of Preoperative

External Beam Radiotherapy Combined With Doxorubicin Followed By Intraoperative Radiotherapy in Patients With Resectable Primary or Recurrent Soft Tissue Sarcoma of the Retroperitoneum

Chairperson: Peter W.T. Pisters. Telephone: 713-794-1572. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: 18 and over.

FHCRC-1205.00, NCI-G97-1331 Phase I Study of Busulfan, Thiotepa, and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Transplantation and Followed by Total Marrow (Skeletal) Irradiation Followed by PBSC Rescue in Patients With High-Risk Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor or Rhabdomyosarcoma

Chairperson: Jean E. Sanders. Telephone: 206-667-4348. Lead organization: Fred Hutchinson Cancer Research Center. Age range: Under 50.

MSKCC-98105, NCI-G99-1500 Phase I Study of Intraperitoneal Mitoxantrone in Patients With Visceral or Retroperitoneal Sarcoma

Chairperson: Murray F. Brennan. Telephone: 212-639-6586. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: over 18.

MDA-ID-97335, NCI-G99-1598 Phase I Study of Preoperative Doxorubicin and External Beam Radiotherapy in Patients With High Risk Soft Tissue Sarcomas of the Extremity or Trunk

Chairperson: Peter W.T. Pisters. Telephone: 713-794-1572. Lead

organization: University of Texas - MD Anderson Cancer Center. Age range: over 16.

MAYO-980105, NCI-T99-0021 Phase I/II Study of Mitomycin, Doxorubicin and Cisplatin Plus ONYX-015 in Patients With Advanced Sarcoma

Chairperson: Evanthia Galanis. Telephone: 507-284-3902. Lead organization: Mayo Clinic Cancer Center. Age range: 18 and over.

EORTC-62001-16003, NOVARTIS-CSTI5710203 Phase I/II Study of STI571 in Patients With Recurrent or Refractory Soft Tissue Sarcoma

Chairperson: Jacob Verweij. Telephone: 31-10-4391338. Lead organization: EORTC Soft Tissue and Bone Sarcoma Group. Age range: 15 and over.